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Paramyxovirus V Proteins Interact with the RNA Helicase LGP2 To
Inhibit RIG-I-Dependent Interferon Induction
Kay Childs,a Richard Randall,b and Stephen Goodbourna
Division of Basic Medical Sciences, St. George’s, University of London, London, United Kingdom,a and Biomolecular Sciences Building, School of Biology, University of St.
Andrews, North Haugh, St. Andrews, United Kingdomb
RIG-I andmda-5 are activated by viral RNA and stimulate type I interferon production. Laboratory of genetics and physiology 2
(LGP2) shares homology with RIG-I andmda-5 but lacks the CARD domains required for signaling. The V proteins of
paramyxoviruses limit interferon induction by binding mda-5 and preventing its activation; however, they do not bind RIG-I
and have not been considered inhibitors of RIG-I signaling. Here we uncover a novel mechanism of RIG-I inhibition in which
the V protein of parainfluenzavirus type 5 (PIV5; formerly known as simian virus type 5 [SV5]) interacts with LGP2 and cooper-
atively inhibits induction by RIG-I ligands. A complex between RIG-I and LGP2 is observed in the presence of PIV5-V, and we
propose that this complex is refractory to activation by RIG-I ligands. The V proteins from other paramyxoviruses also bind
LGP2 and demonstrate LGP2-dependent inhibition of RIG-I signaling. This is significant, because it demonstrates a general
mechanism for the targeting of the RIG-I pathway by paramyxoviruses.
Virus infection stimulates innate immune responses in the host,among which the production of type I interferon (IFN) plays
a critical role in restricting virus replication, via the upregulation
of a large number of IFN-stimulated genes, and through themod-
ulation of subsequent adaptive immune responses (reviewed in
reference 37). IFN induction is triggered by the recognition of
pathogen-associated molecular patterns (PAMPs), principally
those associated with viral nucleic acids, which are seen as foreign
by cellular pattern recognition receptors (PRRs; reviewed in ref-
erence 21). The RNA helicases RIG-I and mda-5 are the two best-
characterized cytoplasmic PRRs; RIG-I preferentially recognizes
RNA molecules with an uncapped 5=-triphosphate in a short re-
gion of blunt double-stranded RNA (dsRNA), while mda-5 rec-
ognizes longer molecules of dsRNA which need not be 5=-
triphosphorylated (13, 16, 32, 33, 42, 44; reviewed in reference
43). Viral RNA binds to the C-terminal regulatory domain (RD)
of RIG-I or mda-5, and it is this region that confers specificity of
PAMP recognition, although the central RNA helicase domain
may also be involved in binding longer RNAmolecules (22, 24, 28,
49, 52). RNA binding causes a conformational change which pro-
motes oligomerization and allows interaction of the N-terminal
CARD domains of RIG-I or mda-5 with the mitochondrial adapter
protein IPS-1 (also known as VISA, MAVS, and CARDIF). This ini-
tiates a signaling cascade leading to activation and nuclear transloca-
tion of the transcription factors IRF-3 andNF-B, which are needed
to turn on transcription of the IFN- gene.
While the interactions between synthetic PAMPs and RIG-I or
mda-5 have been well characterized, the types of PAMPs recog-
nized by RIG-I and mda-5 during viral infections are less clear.
Mice lacking mda-5 showed no IFN induction in response to the
picornavirus encephalomyocarditis virus (EMCV) (10, 17), con-
sistent with the generation of a dsRNA replicative intermediate for
this virus; RIG-I0/0 mice showed severely impaired IFN induction
in response to a range of both positive- and negative-stranded
RNA viruses (17), leading to the view that RIG-I was the only PRR
essential for IFN induction by the majority of RNA viruses. How-
ever, it has become clear that, in many cases, both mda-5 and
RIG-I are important for mounting full IFN responses. For exam-
ple, both helicases contribute to IFN induction in infections by the
paramyxoviruses measles virus (MeV) (14) and Sendai virus
(SeV) (11, 17). The nature of PAMPs generated during infection
remains largely unknown. Paramyxoviruses appear to generate a
range of concentrations of the mda-5 protoligand dsRNA during
the course of an infection (5, 53), while RIG-I ligands are poten-
tially generated by the uncapped 5=-triphosphorylated genomic
RNA or the leader RNA. Interestingly, recent work has demon-
strated that RNA from the LII region of the L gene of parainflu-
enzavirus type 5 (PIV5) can induce IFN- through anmda-5- and
RNaseL-dependent pathway (26). Paramyxoviruses are also well
known as efficient inducers of IFN as a result of the generation of
defective interfering (DI) particles in working stocks (6, 15, 18, 35,
47); these DI particles can be either internal deletions or copyback
genomes, and the latter have been shown to be potent activators of
RIG-I (4, 48).
A third RNA helicase, laboratory of genetics and physiology 2
(LGP2), shares significant homology with RIG-I and mda-5
within the helicase domain but lacks the CARD domains and is
therefore thought incapable of signaling directly. Initial cell cul-
ture experiments suggested that LGP2 acted as a negative regula-
tor of IFN induction due to its ability to bind dsRNA but not
trigger downstream signaling (20, 38, 54). However, the genera-
tion of LGP2 knockout mice revealed a more complex role for
LGP2 in regulation of the IFN response. Consistent with a nega-
tive regulatory role for LGP2 in IFN synthesis, LGP2o/o mouse
embryonic fibroblasts (MEFs) showed increased levels of IFN-
mRNA in response to poly(I · C) and vesicular stomatits virus
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(VSV), and the mice were more resistant to VSV infection than
their wild-type (wt) counterparts (51). However, more surpris-
ingly, LGP2o/o macrophages made less IFN in response to EMCV
than wild-type cells, virus titers were higher, and the mice were
more sensitive to EMCV infection. This suggested that LGP2
could play both positive and negative roles in IFN induction and
that there may be distinct effects depending on the virus and
whether it is recognized by RIG-I (as seen with VSV) ormda-5 (as
seen with EMCV). More recently, another study has suggested
that LGP2 can also be a positive regulator for some viruses that
activate RIG-I (40).
Viruses have evolved numerousmechanisms to counteract the
IFN response, and their ability to do this effectively is critical to
their ability to establish an infection and often influences their
pathogenicity. Paramyxoviruses are known to block both type I
IFN signaling and type I IFN induction (reviewed in reference 37).
In the case of parainfluenza virus type 5 (PIV5; formerly known as
SV5), both of these functions are a property of themultifunctional
V protein. In contrast to the wild-type virus, which induces neg-
ligible amounts of IFN-, PIV5 lacking a functional V protein
induces large amounts of IFN- and grows very poorly in IFN-
competent cells (12, 35). Studies on other paramyxoviruses have
also confirmed the importance of the V protein for virulence and
the control of IFN production (see, for example, references 30, 36,
and 41). The V protein limits IFN induction by binding to the
helicase domain of mda-5, preventing dsRNA binding and conse-
quent oligomerization and activation of mda-5 (2, 7, 8); in con-
trast, V does not bind toRIG-I directly or inhibit IFN induction by
overexpressed RIG-I (7). Given the observations revealing that
paramyxoviruses are able to activate both mda-5 and RIG-I, the
reportedmda-5-specific targeting by the V proteins would poten-
tially leave these viruses prone to IFN induction through the acti-
vation of RIG-I. In at least some cases, additional mechanisms
have been described whereby paramyxoviruses inhibit RIG-I
function; thus, the C protein of SeV is able to inhibit RIG-I (48),
while the W protein of Nipah virus acts to inhibit IRF-3 (46).
However, many paramyxoviruses do not encode C orW proteins;
to date, no general mechanism for RIG-I inhibition has been de-
scribed for paramyxoviruses. Here we show that the V proteins of
all paramyxoviruses tested interact directly with LGP2, confirm-
ing and extending previous observations (31). The physiological
significance of this interactionwas previously unknown.We show
that this interaction inhibits the activation of RIG-I by specific
PAMPs. These results are significant, because they demonstrate a
general mechanism for the targeting of the RIG-I pathway by
paramyxoviruses.
MATERIALS AND METHODS
Plasmids. The IFN-ß promoter reporter plasmid pIF(116)lucter, the
constitutive ß-galactosidase reporter plasmid pJatLacZ, the expression
vector pEFplink2, pEF.mda-5 and pEF.RIG-I, pEF.Flag.mda-5 and
pEF.Flag.RIG-I, pEF.mda-5N, pEF.RIG-IN, and expression vectors
for paramyxovirus V and P proteins and deletion mutants of V have been
previously described (8). To create a plasmid expressing the C terminus of
PIV5-V with a V5 tag, pEF.V5.PIV5-VN, a BamHI-XbaI fragment en-
coding amino acids 125 to 222 of PIV5-V, was cut out of pEF.PIV5-V
and cloned between the BamHI and XbaI sites of pEF.V5.plink2.
pEF.RIGCARD (a plasmid expressing only the CARD domains of RIG-I)
was constructed by inserting a fragment encoding amino acids 1 to 226
between theNcoI and EcoRI sites of pEFplink2. A cDNA clone for human
LGP2 was obtained from the IMAGE Consortium (clone 4865798), and
the open reading frame (ORF) was cloned into pEFplink2 derivatives
permitting expression of N-terminally V5- and Flag-tagged inserts to
create pEF.Flag.LGP2 and pEF.V5.LGP2. pEF.Flag.LGP2(K634E) and
pEF.Flag.LGP2IV were generated by PCR site-directed mutagenesis us-
ing standard methods.
For yeast two-hybrid assays, cDNAs were cloned into pGBKT7 or
pGADT7 (Clontech) for expression of proteins as GAL4 DNA-binding
domain (DBD) or GAL4 activation domain (AD) fusions, respectively.
pGBKT7.RIG-I, pGBKT7.mda-5(676-816), and pGADT7 plasmids con-
taining cDNAs from the paramyxovirus V proteins, have been previously
described (8). pGADT7.PIV5-VN104 and pGADT7.PIV5-VC174
were created from pEF.PIV5-VN104 and pEF.PIV5-VC174 (35).
pGBKT7.LGP2 was created by cloning the LGP2 cDNA into the NcoI and
EcoRI sites of pGBKT7. A PciI-BspHI fragment encoding the N-terminal
145 amino acids of LGP2 was cloned into the NcoI site of pGBKT7 to
create pGBKT7.LGP2(1-145). A fragment encoding amino acids 327 to
465 of LGP2 was generated by PCR incorporating an NcoI site at the 5=
end, whichwas then cloned into theNcoI site of pGBKT7. TheC terminus
of LGP2 (amino acids 465 to 678) was cloned as an NcoI (partial)-EcoRI
fragment. pGBKT7.mda-5(676-816)IV was created by joining two PCR
products through an engineeredXhoI site. The first PCRproduct encoded
amino acids 676 to 719 and contained an XhoI site immediately after the
A719 codon, and the second encoded amino acids 732 to 816, with an
XhoI site immediately 5= of the Y732 codon. The resulting product con-
tained sequences encoding two amino acids (Leu and Glu) in place of the
deleted sequences encoding amino acids 720 to 731 derived from theXhoI
site. Similarly, pGBKT7.LGP2(327-465)IVwas created by joining a frag-
ment encoding amino acids 327 to 368 to a fragment encoding amino
acids 381 to 465 through an XhoI site, replacing amino acids 369 to 380
with Leu and Glu. LGP2 with helicase motif IV replaced with the equiva-
lent sequence from RIG-I [LGP2(IV)R] was made by replacing an AccI-
BmrI fragment with a synthesized DNA molecule (Eurofins) containing
the desired sequence by which amino acids 369 to 380 of LGP2 were
replaced with amino acids 630 to 640 of RIG-I. pGBKT7.RIG-I(225-925)
was previously described in reference 8, and pGBKT7.RIG-I(225-
925)(IV)L was created by replacing a BamHI-NciI fragment with a syn-
thesized sequence (Eurofins) in which amino acids 630 to 640 of RIG-I
were replaced with amino acids 369 to 380 of LGP2.
Cells, transfections, and siRNAs. HEK293 (ATCC CRL-1573) Vero
(ATCC CCL-81) and A549/pr(IFN-).GFP (6) cells were maintained in
Dulbecco’s modification of Eagle’s combined medium (DMEM) with
10% fetal bovine serum (FBS) and penicillin-streptomycin. Transfections
were carried out using linear polyethyleneimine (PEI) (Polysciences Inc.,
Warrington, PA) (molecular weight [MW], 25,000) or Lipofectamine
(Invitrogen) under standard conditions. Luciferase and -galactosidase
assays were carried out 48 h after transfection, and luciferase activity was
corrected to -galactosidase activity. The data presented in each of the
figures represent the means of the results of at least three independent
experiments, with error bars shown. Statistical significance was deter-
mined by paired t tests. Small interfering RNAs (siRNAs) corresponding
to LGP2 were composed of an equimolar combination of two LGP2-
specific siRNAs from Qiagen (catalog no. S100470288 and S100470295),
the mda-5 siRNA was Hs_IFIH1_2 (Qiagen catalog no. S100445851), the
RIG-I siRNA was Hs_DDX58_1 (Qiagen catalog no. S100361809), and
the control siRNA corresponded to an unrelated protein, LRRC37A
(Qiagen catalog no. S100622874).
Virus infections and inductions.Where indicated, cells were infected
at a multiplicity of infection (MOI) of 5 with the W3A strain of PIV5 in
DMEMplus 2% FBS. Induction of cells with poly(I · C) was carried out as
described previously (7). Poly(dA-dT) (Sigma; catalog no. P0883) was
transfected into cells by the use of PEI, and RNA from influenza virus-
infected cells and RIG-Ipan RNA were transfected using Lipofectamine
(Invitrogen). RNA from influenza virus-infected cells wasmade by infect-
ing a confluent 9-cm-diameter plate of HEK293 cells with Influenza
A/Duck/Singapore/97 (a gift from J. McCauley, NIMR, London, United
Childs et al.
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Kingdom) in 3.5 ml of serum-free DMEM at an MOI of 5. Cells were
incubated for 2 h, after which a further 6.5 ml of DMEM plus 2% FBS
was added and the mixture was incubated for a further 6 h before
harvesting. RIG-Ipan RNA was synthesized from an oligonucleotide
template (5=-GACACACACACACACACACACAAAAAAAGTGTGTGT
GTGTGTGTGTGTCTATAGTGAGTCGTATTA-3=; MWG-Eurofins)
hybridized to a T7 promoter oligonucleotide (5=-TAATACGACTCACT
ATAG-3=; MWG-Eurofins) by the use of a T7 polymerase in vitro tran-
scription kit (MegaShortScript; Ambion) and gel purified; the ability of
this material to induce IFN expression is completely abolished by treat-
ment with alkaline phosphatase.
Immunofluorescence and fluorescence microscopy. For immuno-
fluorescence experiments, cells grown on glass coverslips were washed in
phosphate-buffered saline (PBS) and then fixed using 4% paraformalde-
hyde and permeabilized with 0.5% Triton X-100. Immunofluorescence
was carried out using the anti-Pk antibody to detect PIV5 P/V and goat
anti-mouse IgG:Texas Red (AbD Serotec). Texas Red and green fluores-
cent protein (GFP) were visualized using a Nikon Eclipse TS100 fluores-
cence microscope. Fluorescence-activated cell sorter (FACS) analysis was
performed on a Beckman-Coulter Cytomics FC500 cytometer, analyzing
for GFP as described previously (6); PIV5 infection was monitored using
an anti-NP monoclonal antibody as the primary antibody and goat anti-
mouse IgG:RPE (AbD Serotec 103009) as the secondary antibody.
Coimmunoprecipitation assays and immunoblotting. To make cell
extracts, 6-cm-diameter dishes of transfected cells were washed in PBS
and then lysed in 500 l of lysis buffer (50 mM Tris-HCl pH [7.5], 150
mMNaCl, 1mMEDTA, 1%NP-40). A 100-l volume of extract was used
for coimmunoprecipitation assays using mouse monoclonal antibodies
against the Flag (Sigma F3165) or V5 (anti-Pk) tags. Complexes were
collected on protein A-Sepharose beads (GE Healthcare), washed thrice
with 1 ml of lysis buffer, and resuspended in sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer. Proteins
were separated by SDS-PAGE, and immunoblotting was performed using
monoclonal antibodies to the Flag or V5 tags (as described above), the
myc tag (Sigma clone 9E10; catalog no. SAB4300605), or -tubulin
(Sigma catalog no. T9026) or polyclonal antibodies to LGP2 (Abcam;
catalog no. ab67270) or mda-5 (AT113) (Alexis Biochemicals; catalog no.
ALX-210-935). Bound primary antibodies were detected using either
horseradish peroxidase (HRP)-conjugated sheep anti-mouse Ig or don-
key anti-rabbit whole antibody (GE Healthcare).
Yeast two-hybrid assays.Combinations of GAL4DBD andGAL4 AD
fusion plasmids were introduced into Saccharomyces cerevisiae strain
PJ69-4 (or CG1945 where indicated) by the use of standard methods.
Double transformants were selected on synthetic dropout (SD) medium
lacking leucine and tryptophan (SD-L-W) and subsequently streaked
onto SD-L-Wmediumalso lacking histidine (SD-L-W-H) and containing
2 to 20 mM 3-aminotriazole (3-AT). Growth was monitored for 4 to 10
days at 30°C.
RESULTS
The V protein of parainfluenza virus 5 (PIV5) interacts with
LGP2. We have previously shown that the V proteins of 13
paramyxoviruses interact with mda-5, blocking its activation by
dsRNA and consequently inhibiting IFN production (2, 7, 8).
However, none of the V proteins tested were able to interact with
RIG-I or block signaling in response to overexpressedRIG-I. Since
the third member of this family, LGP2, exhibits greater homology
to mda-5 than RIG-I, we tested whether the PIV5 V protein could
also interact with LGP2. Indeed, we found that PIV5-V coimmu-
noprecipitated with bothmda-5 and LGP2, but not with RIG-I, in
extracts from transiently transfected cells (Fig. 1A) and also that
LGP2 could be coprecipitated with the V protein in PIV5-infected
cells (Fig. 1B). These interactions were not affected by treatment
of the cells with dsRNA (Fig. 1A). We then confirmed this inter-
action using the yeast two-hybrid assay (Fig. 1C) and extended the
results to show that the unique C-terminal region comprising
amino acids 175 to 222 of PIV5-V, but not the N-terminal 104
amino acids, were required for binding LGP2 (Fig. 1D). This is the
same region of PIV5-V that is required for binding to mda-5. Our
studies of mda-5 identified amino acids 676 to 816 of mda-5 as
sufficient to bind the V proteins from all 13 paramyxoviruses (7);
thus, to determine whether the corresponding section of LGP2
was also sufficient to bind PIV5-V, we generated plasmids ex-
pressing N-terminal (amino acids 1 to 145), central (amino acids
327 to 465), andC-terminal (amino acids 465 to 678) fragments of
LGP2 and assessed their ability to bind to PIV5-V in a yeast two-
hybrid assay. The central fragment comprising amino acids 327 to
465 is equivalent to amino acids 676 to 816 of mda-5, and this was
sufficient to bind PIV5-V (Fig. 1E), indicating that V targets the
same region of both helicases.
Mda-5, RIG-I, and LGP2 are characterized as DExH RNA he-
licases by the presence of six conserved signature motifs desig-
nated I to VI. The region containing the PIV5-V protein binding
site on mda-5 and LGP2 spans motifs IV and V, which are pro-
posed to play a role in RNA binding (3) (Fig. 1F). Since motif V is
completely conserved between mda-5, LGP2, and RIG-I, it is un-
likely to be critical for PIV5-V binding, as PIV5-Vdoes not bind to
RIG-I. However, motif IV and the residues immediately to either
side of it are conserved between mda-5 and LGP2 but are more
divergent in RIG-I, so we decided to analyze the role ofmotif IV in
PIV5-V binding. Deletion of motif IV abolished binding of
PIV5-V to both mda-5(676-816) and LGP2(327-465) (Fig. 1G).
Replacement of the LGP2 IVmotif with that of RIG-I [LGP2(IV)R]
impaired, but did not abolish, binding to PIV5-V, while the recipro-
cal replacement [RIG-I(IV)L] failed to confer PIV5-V binding to
RIG-I (Fig. 1H). Thus, motif IV of the helicase domain is necessary
but not sufficient to determine the specificity of PIV5-V recruitment.
PIV5-V inhibits IFN induction by both mda-5 and RIG-I in
the presence of LGP2. Parisien et al. also recently reported an
interaction between paramyxovirus V proteins and LGP2 but did
not report any consequences of this interaction for IFN induction
(31). To characterize the behavior of LGP2, we first looked at the
effects of LGP2 on IFN induction by overexpression of RIG-I or
mda-5 (i.e., in the absence of added PAMPs). In agreement with
previous studies (29, 34, 39), we found that overexpression of
LGP2 stimulated IFN induction by mda-5 in Vero cells but, in
contrast, inhibited IFN induction by RIG-I (Fig. 2A).We repeated
these experiments in HEK293 cells and obtained similar results
with respect to RIG-I inhibition, although the magnitude of acti-
vation of mda-5 was considerably higher than that observed in
Vero cells (Fig. 2B). The expression of mda-5 and RIG-I was con-
firmed by immunoblotting, and we also verified that increasing
levels of LGP2 plasmid correlated with increasing levels of LGP2
protein (see Fig. S1A and S1B in the supplemental material). One
trivial explanation for the inhibition of RIG-I by LGP2 is that
overexpression of LGP2 sequesters an endogenous RNA ligand
that is responsible for the activation of the ectopically expressed
RIG-I. To eliminate this possibility, we constructed a vector ex-
pressing a K634E mutant form of LGP2; this alteration has been
previously shown to completely abolish dsRNA binding (23, 34).
This point mutant is expressed to a level similar to that of the
wild-type LGP2 (see Fig. S1C in the supplemental material) and
was just as effective as the wild-type LGP2 in its ability to inhibit
RIG-I (Fig. 2C).
V Proteins Inhibit RIG-I through LGP2
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We then studied the effect of expressing PIV5-V on the ability
of LGP2 to regulate overexpressed mda-5 or RIG-I. Consistent
with the ability of the V protein to inhibit IFN induction by bind-
ing tomda-5, we found that the capacity of LGP2 to stimulate IFN
induction bymda-5 was inhibited by PIV5-V in a dose-dependent
manner (Fig. 2D). Increasing levels of PIV5-V protein were con-
firmed by immunoblotting (see Fig. S1D in the supplemental ma-
terial). More interestingly, when PIV5-V was cotransfected with
LGP2 and RIG-I, the inhibition of RIG-I by LGP2 was enhanced
by the presence of the V protein (Fig. 2E). To confirm this
observation, we repeated the experiment in HEK293 cells using
limited concentration of a LGP2 plasmid chosen to have little
or no effect on RIG-I activity. Figure 2F shows that the V pro-
tein could significantly inhibit overexpressed RIG-I; impor-
tantly, consistent with our previous results (7), this inhibition
was not seen in the absence of coexpressed LGP2. The V protein
could also cooperate with the LGP2 K634E mutant in inhibit-
ing RIG-I (Fig. 2G), confirming that dsRNA binding is not
needed for inhibition of RIG-I.
Since the C terminus of the PIV5-V protein is sufficient to bind
LGP2 (see Fig. 1D), we investigated whether this region of PIV5-V
is also sufficient for inhibition of RIG-I. RIG-I was cotransfected
with LGP2 and full-length PIV5-V, PIV5-VN (which lacks 125
amino acids of the N terminus), or PIV5-VC (which lacks 48
amino acids of the C terminus). PIV5-VN, but not PIV5-VC,
was able to inhibit RIG-I in the presence of LGP2 as effectively as
full-length PIV5-V (Fig. 2H) despite similar expression levels (see
Fig. S1E in the supplemental material), thus demonstrating that
the C terminus of PIV5-V is sufficient both to bind LGP2 and to
inhibit RIG-I in an LGP2-dependent manner. This function is
FIG 1 The V protein of PIV5 interacts with LGP2. (A)HEK293 cells were transfected with pEF.PIV5-V and pEF.Flag.mda-5, pEF.Flag.RIG-I, or pEF.Flag.LGP2.
At 30 h after transfection, cells were either mock treated or induced with poly(I · C) for 8 h prior to harvesting. Cell extracts were subjected to immunoprecipi-
tation (IP) with anti-Flag, and proteins present in the immunoprecipitate were analyzed by immunoblotting (IB) using anti-Flag or an antibody against the V
protein. IB was also carried out on the cell extracts to confirm expression of the V protein. (B) HEK293 cells transfected with pEF.Flag.LGP2 were mock infected
or infected with PIV5 for 12 h prior to harvesting. Extracts were subjected to IP with an antibody against V, and proteins present in the immunoprecipitate were
analyzed by IB with anti-LGP2. Expression of LGP2 and V was confirmed by IB. (C, D, E, G, and H) Interactions between protein pairs were investigated using
the yeast two-hybrid assay. Yeast cells were transformed with (C) empty pGBKT7 vector or pGBKT7 expressing mda-5, RIG-I, or LGP2 as a GAL4 DBD fusion
and a plasmid expressing PIV5-V as a GAL4AD fusion; (D) empty pGBKT7 vector or pGBKT7 expressing LGP2 as a GAL4DBD fusion and a plasmid expressing
PIV5-V lacking theN-terminal 104 amino acids (VN104) or theC-terminal 48 amino acids (VC174) asGAL4AD fusions; (E) the indicated fragments of LGP2
as a GAL4 DBD fusion and a plasmid expressing PIV5-V as a GAL4 AD fusion; (G) amino acids 676 to 816 of mda-5, mda-5(676-816) with motif IV deleted
(IV), or amino acids 327 to 465 of LGP2 or LGP2(327-465) withmotif IV deleted as GAL4DBD fusions and a plasmid expressing PIV5-V as a GAL4AD fusion;
or (H) LGP2, LGP2 with motif IV replaced with the corresponding sequence from RIG-I [LGP2(IV)R], the helicase domain of RIG-I (amino acids 225 to 925),
or the helicase domain of RIG-I with motif IV replaced with the corresponding sequence from LGP2 [RIG-I(IV)L] as GAL4 DBD fusions and a plasmid
expressing PIV5-V as a GAL4 AD fusion. Transformants were initially selected on SD-L-W and then streaked onto SD-L-W and SD-L-W-Hwith 3-AT at 5 mM
(C, E, and G), 10 mM (H), or 20 mM (D). (F) Sequence alignment of mda-5, LGP2, and RIG-I within the region of mda-5 and LGP2 that binds PIV5-V. Amino
acids present inmda-5 conserved in LGP2 and RIG-I are highlighted. IV andV denote helicasemotifs IV andV, and * indicates the region encompassing domain
IV that is deleted or swapped in the IV and (IV)R/L constructs.
Childs et al.
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distinct from the effect of V on mda-5, since cooperative inhibi-
tion of RIG-I signaling by LGP2 and V was observed in the pres-
ence of an siRNA against mda-5 (see Fig. S2 in the supplemental
material).
LGP2 and PIV5-V cooperatively inhibit IFN induction by
RIG-I ligands.We previously demonstrated that signal transduc-
tion in response to overexpressed RIG-I could not be antagonized
by paramyxovirus V proteins (7). The results described above in-
dicate that this situation can be altered by coexpression of LGP2,
implying that, in our previous experiments, overexpression of
RIG-Imay have overcome LGP2-mediated inhibition byV simply
by disrupting the RIG-I/LGP2 ratio. An important question to
arise from this is whether V proteins can antagonize RIG-I activa-
tion in response to specific PAMPs under conditions in which
RIG-I and LGP2 levels are not manipulated. We did not previ-
ously test this because of the lack of knowledge about the distinc-
tion between mda-5 and RIG-I ligands, but several PAMPs have
recently been characterized that activate only RIG-I. RNApurified
from influenza virus-infected cells (16) and poly(dA-dT) (1, 9)
have both been demonstrated to induce IFN expression in a RIG-
I-dependent manner with little or no dependence on mda-5. In
addition, we synthesized by in vitro transcription a short panhan-
dle RNA that we predicted would be a potent activator of RIG-I
(RIG-Ipan RNA). To confirm the selectivity of these PAMPs for
RIG-I, we used specific siRNAs or the expression of dominant-
negative forms of RIG-I andmda-5 (see Fig. S3 in the supplemen-
tal material). Only the RIG-I siRNA and the dominant-negative
form of RIG-I (RIG-IN), and not the mda-5 siRNA or the
dominant-negative form of mda-5 (mda-5N), were able to in-
hibit IFN induction by poly(dA-dT), influenza virus RNA, and
RIG-Ipan RNA. Furthermore, IFN induction by overexpressed
RIG-I, but notmda-5, was stimulated upon addition of these RIG-
I-specific PAMPs.
We therefore tested whether the V protein of PIV5 was able to
antagonize induction by these ligands. Figure 3A and B show that
expression of PIV5-V, but not PIV5-P, inhibited IFN induction by
all three RIG-I-specific PAMPs. We also tested PIV5 proteins NP,
SH, M, F, HN, and L, but none of these were able to limit induc-
tion by poly(dA-dT) inHEK293 cells (data not shown), indicating
that V is the only PIV5 protein able to inhibit IFN induction
through the RIG-I pathway. To confirm the inhibition of IFN
induction by RIG-I ligands in the context of a virus infection, we
sought to determine whether preinfection of cells with PIV5
would limit the amount of IFN induced by subsequent challenge
with a RIG-I ligand. To monitor IFN induction, we used a stable
A549 cell line containing a GFP reporter gene under the control of
the IFN- promoter [A549/pr(IFN-).GFP] (6). Challenging
mock-infected cells with poly(I · C) or the RIG-I activators
(poly(dA-dT) or RNA from influenza virus-infected cells resulted
in a significant induction of GFP-positive cells (Fig. 3C). Infection
with the W3A strain of PIV5 gave a much smaller number of
GFP-positive cells, despite effectively all cells being infected. PIV5
FIG 2 PIV5-V inhibits IFN induction by mda-5 and RIG-I in the presence of LGP2. (A) Vero cells were transfected with pIF(116)lucter, pJatlacZ, 80 ng of
pEF.mda-5 or pEF.RIG-I, and 0 ng (lanes 1 and 2), 1 ng (lane 3), 10 ng (lane 4), 100 ng (lane 5), 200 ng (lane 6), or 388 ng (lane 7) of pEF.LGP2. Total amounts
of plasmid DNA were kept equal within experiments by adding empty pEFplink2 vector. (B) HEK293 cells were transfected with pIF(116)lucter, pJatlacZ, 2
ng of pEF.mda-5 or pEF.RIG-I, and 0 ng (lanes 1 and 2), 10 ng (lane 3), or 400 ng (lane 4) of pEF.LGP2. (C) HEK293 cells were transfected with
pIF(116)lucter, pJatlacZ, pEFplink2 (lane 1), pEF.RIG-I (lanes 2 to 4), and a plasmid expressing either LGP2 or LGP2(K634E). (D)Vero cells were transfected
with pIF(116)lucter, pJatlacZ, pEFplink2 (lane 1), 80 ng of pEF.mda-5 (lanes 2 to 6), 40 ng of pEF.LGP2 (lanes 3 to 6), and 40, 80, or 160 ng of pEF.PIV5-V
(lanes 4 to 6). (E) Vero cells were transfected with pIF(116)lucter, pJatlacZ, pEFplink2 (lane 1), 80 ng of pEF.RIG-I (lanes 2 to 5), 10 ng of pEF.LGP2 (lanes
3 to 5), and 10 ng or 50 ng of pEF.PIV5-V (lanes 4 and 5). The additional inhibition observed in the presence of LGP2 and Vwas statistically significant (i.e., P
0.05). (F) HEK293 cells were transfected with pIF(116)lucter, pJatlacZ, pEFplink2 (lane 1), 2 ng of pEF.RIG-I (lanes 2 to 7), 10 ng of pEF.LGP2 (lanes 5 to 7),
and 10 ng (lanes 3 and 6) or 100 ng (lanes 4 and 7) of pEF.PIV5-V. The additional inhibition observed in the presence of LGP2 and V was statistically significant
(i.e., P 0.05). (G)HEK293 cells were transfectedwith pIF(116)lucter, pJatlacZ, pEFplink2 (lane 1), pEF.RIG-I (lanes 2 to 6), and plasmids expressing LGP2,
LGP2(K634E), or PIV5-V. (H) HEK293 cells were transfected with pIF(116)lucter, pJatlacZ, pEFplink2 (lane 1), 2 ng of pEF.RIG-I (lanes 2 to 9), 10 ng of
pEF.LGP2 (lanes 6 to 9), and 20 ng of pEF.PIV5-V (V), pEF.PIV5-VN125 (VN), or pEF.PIV5-VC174 (VC).
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preinfection was able to reduce the number of cells responding to
both mda-5 and RIG-I stimulation to background levels (FACS
analyses of influenza virus RNA samples as a representative data
set demonstrated that the presence of productive PIV5 infection
lowers the number of cells responding to the influenza virus RNA
RIG-I ligand by about 80%), suggesting that wt PIV5 infection is
able to potently inhibit IFN- induction in response to stimula-
tion of either mda-5 or RIG-I. We have confirmed this in
transient-transfection assays of HEK293 cells (Fig. 3D).
We next investigated the effects of LGP2 expression on the
induction of IFN by defined ligands. Consistent with its role as an
inhibitor of RIG-I and an activator of mda-5, the expression of
exogenous LGP2 inhibited IFN induction by poly(dA-dT), influ-
enza virus RNA, and RIG-Ipan RNA and stimulated induction by
poly(I · C) (Fig. 4A). To examine the consequences of PIV5-V
expression with respect to the LGP2-mediated effects on induc-
tion, we used a limiting concentration of LGP2plasmid in order to
observe the expected cooperativity between PIV5-V and LGP2.
Under these conditions, the induction of reporter activity by
poly(dA-dT), RNA from influenza virus-infected cells, or RIG-
Ipan RNA was only moderately inhibited by LGP2 alone and was
either unaffected or slightly inhibited by PIV5-V alone (Fig. 4B, C,
and D). However, the combination of PIV5-V and LGP2 resulted
in significant inhibition of IFN induction by the RIG-I-dependent
inducers. Therefore, PIV5-V is able to synergize with LGP2 to
limit IFN induction in response to RIG-I ligands. In the case of the
mda-5 ligand poly(I · C), LGP2 stimulated IFN induction whereas
the PIV5-V protein alone was sufficient to achieve a 75% reduc-
tion in IFN- promoter activity (Fig. 4E). In the presence of both
PIV5-V and LGP2, the result was the same as for PIV5-V alone;
FIG 3 PIV5-V inhibits IFN induction by RIG-I ligands. (A) HEK293 cells were transfected with pIF(116)lucter, pJatlacZ, and pEFplink2, pEF.PIV5-V, or
pEF.PIV5-P. At 30 h after transfection, cells were induced with poly(dA-dT), RNA purified from influenza virus-infected cells, or RIG-Ipan RNA for 16 h prior
to harvesting for luciferase and -galactosidase assays. (B) Expression of PIV5-V and -P was confirmed by immunoblotting with an anti-V/P antibody. (C)
A549/pr(IFN-).GFP cells were mock infected or infected with the W3A strain of PIV5 at an MOI of 5 for 24 h. Cells were then induced with poly(I · C),
poly(dA-dT), RNA from uninfected cells (mock RNA), or RNA from influenza virus-infected cells (flu RNA) for a further 24 to 48 h. Expression of GFP was
visualized by fluorescencemicroscopy. To verify that themajority of cells had been infected, PIV5 P/V protein expressionwas visualized by immunofluorescence
using the anti-Pk antibody. (D)HEK293 cells were transfected with pIF(116)lucter and pJatlacZ. At 24 h after transfection, cells were either mock infected or
infected with PIV5 W3A at an MOI 5 and then induced 6 h later with either poly(I · C) or influenza virus RNA for 16 h prior to harvesting for luciferase and
-galactosidase assays.
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thus, activation by LGP2was overcome by PIV5-V, but no further
reduction in activity was observed.
Next we used sufficient PIV5-V to significantly inhibit the in-
duction of IFN in the absence of additional LGP2 and then inves-
tigated whether the PIV5-V-mediated inhibition could be dis-
rupted by an siRNA targeted to endogenous LGP2. Figure 4F
shows that the inhibition of IFN induction by influenza virus RNA
was dependent on the presence of endogenous LGP2, since it was
specifically abolished by an siRNA directed against LGP2; in con-
trast, PIV5-V was able to inhibit IFN induction by the mda-5
agonist, poly(I · C), when either the control or LGP2 siRNAs were
used (Fig. 4G).
LGP2 binding andRIG-I inhibition are general properties of
paramyxovirus V proteins.We then tested the V proteins from a
number of other paramyxoviruses for their ability to interact with
LGP2.We found that, in addition to PIV5-V, the V proteins from
Sendai, Hendra, Menangle, Mapuera, Salem, mumps, measles,
Nipah, Tioman, and Newcastle disease viruses and human PIV2
(hPIV2) and porcine rubulavirus (PoRV) were all able to interact
with LGP2 (Fig. 5A).
Amino acids 327 to 465 of LGP2, which were sufficient to bind
PIV5-V (see Fig. 1E), were also sufficient to bind at least eight of
the viral V proteins, indicating that the binding site for all V pro-
teins is conserved and is also shared between mda-5 and LGP2.
Parisien et al. also reported an interaction between V proteins and
LGP2 and mapped it to amino acids 351 to 479, which is in close
agreement with our data (31). The V proteins from Sendai and
Salem viruses could also independently bind to the C-terminal
fragment encoding amino acids 465 to 678 of LGP2. Interestingly,
we had previously observed that, while all the V proteins bound to
amino acids 676 to 816 of mda-5, the V proteins from PIV5 and
from Menangle and Salem viruses also made additional contacts
with other parts of the protein (8). Although Salem virus V binds
to additional sites within bothmda-5 and LGP2, they appear to be
different, since it binds to a site N-terminally oriented to the con-
served binding site in mda-5 (amino acids 287 to 458) and not to
the C terminus.
Next, we examined the ability of these other V proteins to
enhance inhibition of RIG-I by LGP2. As previously observed,
none of these V proteins alone have any significant effect on IFN
induction by RIG-I overexpression (Fig. 5B, white bars); however,
when they were cotransfected with a small amount of LGP2 plas-
mid, all 13 V proteins effectively inhibited RIG-I signaling (Fig.
5B, gray bars). In contrast, the PIV5 P protein, which does not
interact with LGP2 (data not shown), does not inhibit RIG-I in the
presence of LGP2 (Fig. 5B, final lane).
Mechanism of inhibition of LGP2 by paramyxovirus V pro-
teins.We next sought to characterize the mechanism of coopera-
FIG 4 LGP2 and PIV5-V cooperatively inhibit IFN induction by RIG-I ligands. (A) HEK293 cells were transfected with pIF(116)lucter, pJatlacZ, and either
pEFplink2 or pEF.LGP2. At 30 h after transfection, cells were induced with poly(dA-dT), RNA from influenza virus-infected cells, RIG-Ipan RNA, or poly(I · C)
for a further 16 h prior to harvesting for luciferase and-galactosidase assays. (B to E)HEK293 cells were transfectedwith pIF(116)lucter, pJatlacZ, and either
pEFplink2 (lanes 1 and 2) or plasmids expressing LGP2 or PIV5-V. At 30 h after transfection, cells were induced with poly(dA-dT) (B), RNA from influenza
virus-infected cells (C), RIG-Ipan RNA (D), or poly(I · C) (E) for a further 16 h prior to harvesting for luciferase and -galactosidase assays. The additional
inhibition observed in the presence of LGP2 and V was statistically significant (i.e., P 0.05). (F and G) HEK293 cells were transfected with pIF(116)lucter,
pJatlacZ, pEFplink2 (lanes 1 and 2), or pEF.PIV5-V (lanes 3 and 4) with either a mixture of 2 siRNAs directed against LGP2 or an siRNA directed against an
unrelated transcript (control siRNA). At 30 h after transfection, cells were induced with either (F) RNA from influenza virus-infected cells or (G) poly(I · C) for
a further 16 h prior to harvesting for luciferase and-galactosidase assays. (H) To verify the effectiveness of the LGP2 siRNAs,HEK293 cells were transfectedwith
a plasmid expressing V5-tagged LGP2 along with no siRNA, a control siRNA, or the LGP2 siRNAs. Cell extracts were immunoblotted with an antibody against
the V5 tag and -tubulin as a loading control.
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tive inhibition of RIG-I by LGP2 and PIV5-V. As discussed above,
we have excluded the possibility that the effect is a consequence of
sequestration of an RNA ligand. To determine whether PIV5-V
and LGP2 limit activation of RIG-I through the helicase domain
or the CARD domain, we compared the abilities of PIV5-V and
LGP2 to block IFN induction by overexpression of full-length
RIG-I or the CARD domains only. In contrast to the effects ob-
served with full-length RIG-I, cotransfection of LGP2 did not in-
hibit induction by RIG-I CARD in either the presence or the ab-
sence of PIV5-V (Fig. 6A). This demonstrates that the inhibitory
effect of LGP2 is operating at the level of RIG-I activation and is
dependent on the helicase domain of RIG-I.
We have shown above that PIV5-V binding to LGP2 is com-
pletely disrupted by a deletion of 12 amino acids in motif IV (see
Fig. 1G). We tested whether this mutation in LGP2 was sufficient
to abolish the inhibition of RIG-I in the presence or absence of
PIV5-V. Interestingly, this mutant retained a limited ability to
inhibit RIG-I in the absence of PIV5-V (Fig. 6B); however, in
contrast to wild-type LGP2, PIV5-V was unable to enhance the
inhibition of RIG-I by LGP2IV. Therefore, the ability of V to
interact with LGP2 is critical to its ability to inhibit RIG-I.
Finally, we looked to see whether we could detect an interac-
tion between RIG-I and LGP2 and, if so, whether it is affected by
the V protein. Figure 6C shows that LGP2 coimmunoprecipitated
with RIG-I in extracts from cells expressing the V proteins from
PIV5 or Sendai virus but not in extracts from cells expressing the P
protein from PIV5. Thus, V proteins promote an interaction be-
tween RIG-I and LGP2, and we propose that this interaction re-
sults in inhibition of IFN induction through the RIG-I pathway.
DISCUSSION
Paramyxoviruses evade the innate immune response by encoding
proteins that inhibit both IFN induction and IFN signaling. We
have previously shown that the V proteins of all paramyxoviruses
FIG 5 All paramyxovirus V proteins interact with LGP2 and inhibit RIG-I in an LGP2-dependentmanner. (A) A further 12 paramyxovirus V proteins were tested for
their ability to interactwithLGP2 inayeast two-hybridassay.Yeast cellswere transformedwithaplasmidexpressing full-lengthLGP2or the indicated fragmentsofLGP2
as GAL4 DBD fusion proteins and a plasmid expressing the indicated paramyxovirus V protein as a GAL4 AD fusion protein. Positive transformants were selected on
SD-L-WandthenstreakedontoSD-L-WandSD-L-W-Hplus5 to20mM3-ATtoassay foran interaction.Due to somebackground transactivationbeingobservedwith
someVproteins in the yeast strain PJ69-4, two-hybrid assayswith hPIV2,Nipah, Tioman, andNDVVproteinswere carried outwith yeast strainCG1945 inwhich no
background transactivation was observed. A plus sign denotes a positive interaction, and a minus sign denotes no interaction. ND, not determined. (B) HEK293 cells
were transfectedwithpIF(116)lucter, pJatlacZ, pEFplink2 (lanes 1 and2), 2ngof pEF.RIG-I (white bars), or 2ngof pEF.RIG-I or 10ngof pEF.LGP2 (grey bars), and
pEFplink2 or a plasmid expressing the V protein from the indicated paramyxovirus or the P protein from PIV5 (PIV5-P).
FIG 6 Paramyxovirus V proteins inhibit RIG-I by interacting with LGP2 and promoting the formation of inactive complexes between RIG-I and LGP2. (A)
HEK293 cells were transfected with pIF(116)lucter, pJatlacZ, pEFplink2 (lanes 1 and 6), a plasmid expressing RIG-I (lanes 2 to 5), a plasmid expressing just
the CARD domains of RIG-I (lanes 7 to 10), and plasmids expressing either LGP2 or PIV5-V as indicated. (B) HEK293 cells were transfected with
pIF(116)lucter, pJatlacZ, pEFplink2 (lane 1), 2 ng of pEF.RIG-I (lanes 2 to 7), and either pEF.LGP2 or pEF.LGP2IV and pEF.PIV5-V where indicated. (C)
HEK293 cells were transfected with a plasmid expressing RIG-I with a Flag tag, pEFplink2 (lanes 1, 3, and 5) or a plasmid expressing LGP2 with a V5 tag (lanes
2, 4, and 6), and a plasmid expressing PIV5-V (lanes 1 and 2), the V protein from Sendai virus with a myc tag (myc.Se-V) (lanes 3 and 4), or the P protein from
PIV5 (PIV5-P) (lanes 5 and 6). Cell extracts were subjected to immunoprecipitation (IP) with an antibody against the Flag tag, and proteins present in the
immunoprecipitate were analyzed by immunoblotting (IB) with an antibody to the V5 or Flag tags. Cell extracts were also blotted using antibodies to the V5 and
myc tags to confirm expression of all proteins.
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tested block IFN induction by binding tomda-5 and inhibiting its
activation by dsRNA (2, 7, 8). Although this feature is clearly ef-
fective for blocking IFN induction through the mda-5 pathway,
paramyxoviruses have been shown to activate RIG-I, raising the
question of whether they also encode mechanism(s) for at least
limiting RIG-I activity. Here we describe a novel mechanism of
inhibition of IFN induction by paramyxovirus V proteins by
which they are able to inhibit RIG-I activation in a manner that
depends upon their interaction with LGP2. Using PIV5-V as a
model system, we show that the V protein is capable of promoting
the formation of a complex between RIG-I and LGP2 which ren-
ders RIG-I unable to respond to RIG-I-specific PAMPs. We pro-
pose a model in which the multifunctional V protein is able to
inhibit both mda-5-dependent and RIG-I-dependent IFN induc-
tion through the formation of distinct inactive complexes (Fig. 7).
The inhibition of RIG-I is mechanistically distinct from the inhi-
bition of mda-5 in that the PRR (RIG-I) is not a direct target.
Our previous work (7) showed that V proteins do not bind
directly to RIG-I and do not inhibit IFN induction by RIG-I over-
expression; however, in the earlier experiments the overexpressed
RIG-I would have been in considerable excess over the endoge-
nous LGP2 level and therefore likely insensitive to LGP2-
mediated repression. It may be significant that a considerable ex-
cess of LGP2 plasmid is required to see effective inhibition of
RIG-I signaling (see Fig. 2A and B). Thus, it is interesting to spec-
ulate that LGP2may not be a very potent inhibitor of RIG-I in the
absence of V and that the role of Vmay be to increase the stability
of the LGP2/RIG-I complex, thus promoting the inhibitory action
of LGP2. It also seems likely that the magnitude of inhibition
would be proportional to the endogenous LGP2 levels. Both LGP2
and RIG-I are IFN-inducible genes, and it is interesting to specu-
late that the V-mediated inhibition of RIG-I activation may be-
come more significant as the levels of these proteins rise. Such a
scenario could be extremely beneficial to viruses.
Several mechanisms have been proposed for the observed in-
hibition of RIG-I by LGP2. First, since LGP2 can bind dsRNA, it
may act to sequester PAMPs from recognition by RIG-I (38, 54);
this is an unlikely explanation of both the V-dependent and
V-independent inhibitions we observed here, because inhibition
was still observed with a mutant form of LGP2 that is unable to
bind to RNA. Additionally, we have been unable to reverse the
inhibition by the addition of excess RIG-I ligand (data not
shown). Second, it has been proposed that LGP2 interacts with
IPS-1 and inhibits IFN induction by competing with IB (IKK)
for binding to IPS-1 (20). This is similarly unlikely as an explana-
tion for our observations, since the block is upstream of RIG-I
activationwhereas both IKK and IPS-1 are downstreamofRIG-I.
The third hypothesis is that LGP2 blocks RIG-I activation through
an inhibitory interaction between the RDof LGP2 andRIG-I (39);
we think this is a likely scenario, and we hypothesize that this is an
intrinsically weak interaction that is stabilized by paramyxovirus
V proteins.We also speculate that the LGP2/RIG-I complex forms
in the absence of RNA and is disrupted by ligand binding to either
RIG-I or LGP2 but is refractory to disruption in the presence of
the V protein. We note that, to date, we have been unable to
provide convincing evidence of a triple complex containing
PIV5-V, LGP2, and RIG-I by immunoprecipitation. It is possible
that the reactive epitopes that we use for immunoprecipitation are
not efficiently recognized in triple complexes or that the binding
of antibody to the triple complex disrupts the association of LGP2/
RIG-I with respect to PIV5-V. Alternatively, the effect of PIV5-V
on the affinity of the LGP2/RIG-I associationmay be indirect (i.e.,
through an intermediate protein) or may be a consequence of
modification of one or both components. The resolution of this
issue awaits further experimentation.
In addition to the novel aspect of inhibition of RIG-I activa-
tion, we observed that IFN induction by the combination of
mda-5 and LGP2 could be completely blocked by overexpression
of PIV5-V. This result is not surprising in that we have previously
shown that paramyxovirus V proteins are potent inhibitors of
mda-5 (2, 7, 8). However, the observations that V proteins bind
LGP2, and that LGP2 stimulates mda-5 activity, raise interesting
issues, namely, whether activation of mda-5 is dependent on
LGP2 as a cofactor (at least in response to some PAMPs) and, if so,
whether the primary inhibitory role of the V protein is acting
through LGP2 rather than mda-5. To distinguish between these
possibilities, it would be necessary to generate a combination of
LGP2 and V that is unable to interact while preserving the inter-
action between these proteins and mda-5. The binding of a com-
mon motif in the V proteins to a common epitope in mda-5 and
LGP2 (31 and our results) makes this a difficult issue to resolve.
Additionally, we have observed that LGP2 mutants that show im-
paired binding to PIV5-V also failed to stimulate mda-5 activity
(data not shown), suggesting that sequences required for V bind-
ing are also involved in mda-5 activation. This may provide the
FIG 7 Inhibition of IFN induction by paramyxovirus V proteins. Paramyxo-
virus V proteins block both mda-5-dependent and RIG-I-dependent IFN in-
duction. Replication potentially generates ligands for both mda-5 and RIG-I,
and transcription of the PIV5 L gene has been shown to generate a ligand for
mda-5 (26). Inhibition of mda-5 occurs through a direct interaction between
V and mda-5 which prevents ligand binding and consequent activation of the
signaling pathway leading to IRF-3 and NF-B activation. V proteins inhibit
RIG-I signaling by interacting with LGP2 and promoting the formation of an
inhibitory complex between RIG-I and LGP2 which is refractory to activation
by viral RNA.
V Proteins Inhibit RIG-I through LGP2
April 2012 Volume 86 Number 7 jvi.asm.org 3419
 o
n
 July 3, 2014 by ST ANDREW
S UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
rationale behind the targeting of this particular sequence by the V
protein, as it disrupts several important aspects of mda-5/LGP2
function, namely, dsRNA binding, homo- and heterodimer for-
mation, and the synergy between mda-5 and LGP2.
In contrast to the data presented here, a recent report suggests
that LGP-2 may play a role in stimulating both mda-5 and RIG-I
activity (40). This is an intriguing observation, not least because
the effect is not seen with all viruses; notably, induction by influ-
enza virus (thought to be entirely dependent upon the generation
of RIG-I ligands) is unaffected by the loss of LGP2. Additionally,
the effects are cell type specific (LGP2 appears to stimulate IFN
induction in MEFs but to suppress induction in HEK293 cells). It
is suggested that LGP2 plays a role in recognizing infecting RNA
virus particles by actively removing proteins from viral ribonucle-
oprotein (RNP) complexes or unwinding complex RNA struc-
tures to facilitate recognition of viral RNA (40). An attractive
model to reconcile these disparate conclusions could be that LGP2
is boundweakly to RIG-I in the absence of PAMP and that it helps
to process incoming PAMPs and present these in such a way as to
stimulate RIG-I; paramyxovirus V proteins could interact with
LGP2 and stabilize LGP2/RIG-I in a nonproductive complex. The
ability of LGP2 to stimulate mda-5 is probably due to a distinct
mechanism. LGP2 does not appear to be an inhibitor of mda-5
and associates with mda-5 only in response to dsRNA (unpub-
lished data). Since LGP2 appears to be a much more avid dsRNA
binding protein than mda-5 (54 and data not shown), we suggest
that LGP2 stimulates mda-5 function by either delivering the
ligand to mda-5 or promoting the formation of LGP2/mda-5
higher-order complexes that then promote downstream signal-
ing; the binding of paramyxovirus V proteins to the RNA binding
domains of both LGP2 and mda-5 would prevent this activation.
The data presented here suggest that paramyxoviruses have
evolved a pleiotropicmechanism for limiting IFN induction, since
the interaction of the V proteins with LGP2 can inhibit the acti-
vation of both mda-5 and RIG-I, albeit with apparently distinct
mechanisms. This elegant solution extends our knowledge on the
mechanisms by which RNA viruses evade innate immune re-
sponses, but it is unlikely to be the only strategy employed by
paramyxoviruses to block the induction of IFN. We note that the
V proteins of paramyxoviruses have also been implicated as inhib-
itors of TBK1 and IKK and the p65 subunit of NF-B (25, 45).
More strikingly, the respiroviruses hPIV1, hPIV3, and bPIV3 do
not encode functional V proteins and appear to evade IFN pro-
duction by a combination of C protein functions and limitation of
the production of PAMPs (5, 19, 27, 30, 50).
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